Translational Windows in Chordoma: A Target Appraisal
Open Access
- 8 July 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 11, 657
- https://doi.org/10.3389/fneur.2020.00657
Abstract
Chordomas are rare tumors that are notoriously refractory to chemotherapy and radiotherapy when radical surgical resection is not achieved or upon recurrence after maximally aggressive treatment. The study of chordomas has been complicated by small patient cohorts and few available model systems due to the rarity of these tumors. Emerging next-generation sequencing technologies have broadened understanding of this disease by implicating novel pathways for possible targeted therapy. Mutations in cell-cycle regulation and chromatin remodeling genes have been identified in chordomas, but their significance remains unknown. Investigation of the immune microenvironment of these tumors suggests that checkpoint protein expression may influence prognosis, and adjuvant immunotherapy may improve patient outcome. Finally, growing evidence supports aberrant growth factor signaling as potential pathogenic mechanisms in chordoma. In this review, we characterize the impact on treatment opportunities offered by the genomic and immunologic landscape of this tumor.This publication has 81 references indexed in Scilit:
- TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancerOncoImmunology, 2013
- Does insulin‐like growth factor 1 receptor (IGF‐1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical studyHistopathology, 2012
- TGF-β and BMP Signaling in Osteoblast Differentiation and Bone FormationInternational Journal of Biological Sciences, 2012
- Recurrent Chromosomal Copy Number Alterations in Sporadic ChordomasPLOS ONE, 2011
- Clinical features distinguish childhood chordoma associated with tuberous sclerosis complex (TSC) from chordoma in the general paediatric populationJournal of Medical Genetics, 2011
- The Insulin-like Growth Factor-1 Receptor–Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood SarcomaCancer Research, 2009
- Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor SarcomasJournal of Clinical Oncology, 2009
- Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathwayBritish Journal of Cancer, 2009
- TGFβ in CancerCell, 2008
- Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisationBritish Journal of Cancer, 2007